Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

SARS-CoV-2 Omicron BA.2.75 临床分离株的特征分析

阅读:3
作者:Ryuta Uraki #,Shun Iida #,Peter J Halfmann #,Seiya Yamayoshi #,Yuichiro Hirata,Kiyoko Iwatsuki-Horimoto,Maki Kiso,Mutsumi Ito,Yuri Furusawa,Hiroshi Ueki,Yuko Sakai-Tagawa,Makoto Kuroda,Tadashi Maemura,Taksoo Kim,Sohtaro Mine,Noriko Iwamoto,Rong Li,Yanan Liu,Deanna Larson,Shuetsu Fukushi,Shinji Watanabe,Ken Maeda,Zhongde Wang,Norio Ohmagari,James Theiler,Will Fischer,Bette Korber,Masaki Imai,Tadaki Suzuki,Yoshihiro Kawaoka

Abstract

The prevalence of the Omicron subvariant BA.2.75 rapidly increased in India and Nepal during the summer of 2022, and spread globally. However, the virological features of BA.2.75 are largely unknown. Here, we evaluated the replicative ability and pathogenicity of BA.2.75 clinical isolates in Syrian hamsters. Although we found no substantial differences in weight change among hamsters infected with BA.2, BA.5, or BA.2.75, the replicative ability of BA.2.75 in the lungs is higher than that of BA.2 and BA.5. Of note, BA.2.75 causes focal viral pneumonia in hamsters, characterized by patchy inflammation interspersed in alveolar regions, which is not observed in BA.5-infected hamsters. Moreover, in competition assays, BA.2.75 replicates better than BA.5 in the lungs of hamsters. These results suggest that BA.2.75 can cause more severe respiratory disease than BA.5 and BA.2 in a hamster model and should be closely monitored.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。